RCKT acquires RCOR for $2.34/sh in stock—a 23% premium to yesterday’s close: https://finance.yahoo.com/news/rocket-pharmaceuticals-acquire-renovacor-extending-100000942.html The nominal deal value is $53M. RCOR went public one year ago via a SPAC merger (#msg-165745950). RCKT (the buyer) went public via a reverse-merger in 2017 (#msg-134563146).